MedTrace Logo

Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

NCT01226602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2012-02-13

No results posted yet for this study

Summary

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

Conditions

  • Blood Flow Speed
  • Coronary Flow Velocity

Interventions

DRUG

AZD6140

P2Y12 receptor antagonist

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Jay Horrow, MD · AstraZeneca

  • Marianne Hartford, MD · CTC, Göteborg

  • Mirjana Kujacic, MD PhD · AstraZeneca, Mölndal Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226602 on ClinicalTrials.gov